Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Sol Gel Technologies Ltd (SLGL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: SLGL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -71.31% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 20.61M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1 | Beta 1.1 | 52 Weeks Range 3.34 - 16.50 | Updated Date 06/30/2025 |
52 Weeks Range 3.34 - 16.50 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.75 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -107.78% | Operating Margin (TTM) -879.63% |
Management Effectiveness
Return on Assets (TTM) -26.82% | Return on Equity (TTM) -49.39% |
Valuation
Trailing PE - | Forward PE 9.34 | Enterprise Value 4668777 | Price to Sales(TTM) 1.7 |
Enterprise Value 4668777 | Price to Sales(TTM) 1.7 | ||
Enterprise Value to Revenue 0.39 | Enterprise Value to EBITDA 0.24 | Shares Outstanding 2785760 | Shares Floating 689337 |
Shares Outstanding 2785760 | Shares Floating 689337 | ||
Percent Insiders 70 | Percent Institutions 24.29 |
Analyst Ratings
Rating 1 | Target Price 4 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Sol Gel Technologies Ltd
Company Overview
History and Background
Sol-Gel Technologies Ltd. (SLGL) was founded in 1997, focusing on the development and commercialization of microencapsulation technologies for the pharmaceutical, cosmetic, and personal care industries. It has evolved from primarily developing drug delivery systems to focusing on dermatology products.
Core Business Areas
- Dermatology Products: Develops and commercializes topical dermatology products, leveraging its microencapsulation technology to enhance drug delivery and efficacy.
- Generic Products: Development of topical generic products
Leadership and Structure
Dr. Alon Seri-Levy serves as Chief Executive Officer. The organizational structure consists of research and development, manufacturing, and commercialization departments.
Top Products and Market Share
Key Offerings
- EPSOLAY: EPSOLAY, is a microencapsulated benzoyl peroxide (BPO) cream indicated for the treatment of papulopustular rosacea in adults. Competitors include other topical and oral rosacea treatments from companies like Galderma and Ortho Dermatologics. Market Share unavailable.
- TWYNE: TWYNE, is a microencapsulated benzoyl peroxide and tretinoin cream indicated for the treatment of acne vulgaris in adults. Competitors include other topical acne treatments from companies like Bausch Health and Allergan. Market Share unavailable.
Market Dynamics
Industry Overview
The dermatology market is driven by increasing demand for skincare and treatment solutions, fueled by an aging population and growing awareness of skin health.
Positioning
Sol-Gel Technologies positions itself as an innovator in topical drug delivery, utilizing its microencapsulation technology to provide differentiated products with improved efficacy and tolerability. Its competitive advantage lies in its proprietary technology.
Total Addressable Market (TAM)
The total market value is substantial. Sol-Gel Technologies addresses a portion of the dermatology market, focusing on rosacea and acne treatments.
Upturn SWOT Analysis
Strengths
- Proprietary microencapsulation technology
- Approved products (EPSOLAY and TWYNE)
- Focus on dermatology with unmet needs
Weaknesses
- Reliance on key products
- Relatively small size compared to competitors
- Dependence on partnerships for commercialization
- History of losses
Opportunities
- Expansion into new dermatology indications
- Partnerships with larger pharmaceutical companies
- Geographic expansion
- Development of new microencapsulation applications
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent expiration
- Potential for generic entry after loss of exclusivity
Competitors and Market Share
Key Competitors
- GILD
- VRX
- ALLK
Competitive Landscape
Sol-Gel Technologies faces competition from larger, more established pharmaceutical companies. Its competitive advantage lies in its proprietary microencapsulation technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by product development and commercialization efforts. Specific growth rates require access to historical financial data.
Future Projections: Future projections are dependent on analyst estimates for revenue growth and profitability improvements. Analyst consensus estimates are not provided due to real-time constraints.
Recent Initiatives: Recent initiatives include the launch of EPSOLAY and TWYNE, as well as ongoing research and development efforts.
Summary
Sol-Gel Technologies is a smaller player in the dermatology market with innovative drug delivery technology, but it faces challenges from larger competitors and its dependence on a limited number of products. Its proprietary technology provides a competitive advantage and opportunity for growth. However, history of losses and small size could be of concern. The launches of EPSOLAY and TWYNE are crucial for driving revenue and achieving profitability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share and analyst estimates are based on available information and may not be precise. Financial data may be outdated. Do your own diligence
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sol Gel Technologies Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-01-23 | CEO & Executive Chairman Mr. Moshe Arkin | ||
Sector Healthcare | Industry Biotechnology | Full time employees 34 | Website https://www.sol-gel.com |
Full time employees 34 | Website https://www.sol-gel.com | ||
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.